S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
BREAKING: Tiny biotech successfully treats blindness (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
BREAKING: Tiny biotech successfully treats blindness (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
BREAKING: Tiny biotech successfully treats blindness (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
Watch SHOCKING Footage of AI Facility with Ties to Elon Musk (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
BREAKING: Tiny biotech successfully treats blindness (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
BREAKING: Tiny biotech successfully treats blindness (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
NASDAQ:DRIO

DarioHealth (DRIO) Stock Forecast, Price & News

$3.28
+0.05 (+1.55%)
(As of 09/29/2023 ET)
Compare
Today's Range
$3.16
$3.30
50-Day Range
$2.60
$3.74
52-Week Range
$2.55
$6.78
Volume
45,482 shs
Average Volume
93,622 shs
Market Capitalization
$89.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.03

DarioHealth MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
83.9% Upside
$6.03 Price Target
Short Interest
Bearish
6.02% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.68mentions of DarioHealth in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.98) to ($1.66) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.66 out of 5 stars

Medical Sector

872nd out of 972 stocks

Diagnostics & Research Industry

2nd out of 2 stocks


DRIO stock logo

About DarioHealth (NASDAQ:DRIO) Stock

DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its user-centric multi-chronic condition digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Move to address most common MSK conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

DRIO Price History

DRIO Stock News Headlines

Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
LifeSci Capital Keeps Their Buy Rating on DarioHealth (DRIO)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Here's what Wall Street expects from DarioHealth's earnings
DarioHealth (DRIO) Gets a Buy from LifeSci Capital
LifeSci Capital Reaffirms Their Buy Rating on DarioHealth (DRIO)
DRIO - DarioHealth Corp.
Dario Announces New Full Suite Employer Contract
Pre-market Movers: EAST, CNVS, DRIO, AGRX, IVA…
See More Headlines
Receive DRIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DarioHealth and its competitors with MarketBeat's FREE daily newsletter.

DRIO Company Calendar

Last Earnings
8/10/2023
Today
9/30/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DRIO
Employees
241
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$6.03
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$4.10
Forecasted Upside/Downside
+83.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-62,190,000.00
Net Margins
-120.19%
Pretax Margin
-216.49%

Debt

Sales & Book Value

Annual Sales
$27.66 million
Book Value
$3.12 per share

Miscellaneous

Free Float
24,670,000
Market Cap
$89.31 million
Optionable
Not Optionable
Beta
1.37

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Erez RaphaelMr. Erez Raphael (Age 50)
    CEO & Director
    Comp: $978.76k
  • Mr. Richard A. Anderson (Age 54)
    Pres
    Comp: $998.42k
  • Mr. Zvi Ben David (Age 62)
    CFO, Treasurer & Sec.
    Comp: $429.05k
  • Dov Oppenheim
    Co-Founder & Production Chief
  • Josh Fischer
    Sr. VP of Operations & Compliance
  • Claudia Levi
    Content & Communications Mang.
  • Mary Mooney
    VP of Marketing
  • Limor Drezner
    VP HR & Chief of Staff
  • Mr. Olivier R. Jarry (Age 62)
    Sr. VP of Strategy & Bus. Devel.
  • Mr. Jean Christophe Muyl
    Head of Commercialization North America













DRIO Stock - Frequently Asked Questions

Should I buy or sell DarioHealth stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DarioHealth in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DRIO shares.
View DRIO analyst ratings
or view top-rated stocks.

What is DarioHealth's stock price forecast for 2023?

2 analysts have issued twelve-month price objectives for DarioHealth's stock. Their DRIO share price forecasts range from $4.10 to $8.00. On average, they anticipate the company's share price to reach $6.03 in the next year. This suggests a possible upside of 83.9% from the stock's current price.
View analysts price targets for DRIO
or view top-rated stocks among Wall Street analysts.

How have DRIO shares performed in 2023?

DarioHealth's stock was trading at $4.28 on January 1st, 2023. Since then, DRIO shares have decreased by 23.4% and is now trading at $3.28.
View the best growth stocks for 2023 here
.

When is DarioHealth's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our DRIO earnings forecast
.

How were DarioHealth's earnings last quarter?

DarioHealth Corp. (NASDAQ:DRIO) announced its earnings results on Thursday, August, 10th. The company reported ($0.58) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by $0.06. The firm earned $6.15 million during the quarter, compared to the consensus estimate of $6.04 million. DarioHealth had a negative trailing twelve-month return on equity of 40.09% and a negative net margin of 120.19%.

What guidance has DarioHealth issued on next quarter's earnings?

DarioHealth updated its second quarter 2023 earnings guidance on Monday, July, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $6.00 million-$6.15 million, compared to the consensus revenue estimate of $6.73 million.

What other stocks do shareholders of DarioHealth own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DarioHealth investors own include Aeterna Zentaris (AEZS), Vascular Biogenics (VBLT), Nano Dimension (NNDM), Pluristem Therapeutics (PSTI), NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), ADMA Biologics (ADMA) and Avadel Pharmaceuticals (AVDL).

What is DarioHealth's stock symbol?

DarioHealth trades on the NASDAQ under the ticker symbol "DRIO."

How do I buy shares of DarioHealth?

Shares of DRIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DarioHealth's stock price today?

One share of DRIO stock can currently be purchased for approximately $3.28.

How much money does DarioHealth make?

DarioHealth (NASDAQ:DRIO) has a market capitalization of $89.31 million and generates $27.66 million in revenue each year. The company earns $-62,190,000.00 in net income (profit) each year or ($1.28) on an earnings per share basis.

How many employees does DarioHealth have?

The company employs 241 workers across the globe.

Does DarioHealth have any subsidiaries?
The following companies are subsidiares of DarioHealth: Labstyle Innovation Ltd., PsyInnovations Inc., PsyInnovations India Private Limited., Upright Technologies Inc., and Upright Technologies Ltd..
Read More
How can I contact DarioHealth?

DarioHealth's mailing address is 8 HaToKhen Street, Caesarea Industrial Park L3, 3088900. The official website for the company is www.mydario.com. The company can be reached via phone at (833) 914-3796, via email at ir@mydario.com, or via fax at 972-4770-4059.

This page (NASDAQ:DRIO) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -